Company
ArtiFex Medical GmbH, founded in 2020 in Vienna as a spin-off from University Hospital Basel, develops a vascular graft platform based on bacterial cellulose. Our approach combines a naturally biocompatible material with controlled, reproducible manufacturing to deliver reliable small-diameter grafts.
Investors
Our work is supported by funding from the FFG (Austrian Research Promotion Agency), by NLC Health Ventures, and by committed angel investors, enabling the scientific, technical and preclinical development of our vascular graft platform.